The FDA initially approved lorlatinib in November 2018 as a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with metastatic NSCLC who have tested positive for ALK (Table 4). This evidence concerns the gene ALK and non-small cell lung carcinoma.